Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

SBRT in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients (RADVAX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03065179
Recruitment Status : Active, not recruiting
First Posted : February 27, 2017
Last Update Posted : October 5, 2020
Sponsor:
Information provided by (Responsible Party):
Hans Hammers, University of Texas Southwestern Medical Center

Results Submitted - Quality Control (QC) Review Has Not Concluded
Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the ClinicalTrials.gov Results Quality Control (QC) review process. Results information is submitted to ClinicalTrials.gov by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on ClinicalTrials.gov (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status : Active, not recruiting
Actual Primary Completion Date : February 20, 2020
Estimated Study Completion Date : January 31, 2021
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 December 28, 2020
January 20, 2021 Submission with QC Comments
2 January 26, 2021
February 12, 2021
3 February 24, 2021